Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 and fluzoparib in advanced lung squamous cell carcinoma
NCT04937972Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa and fluzoparib in squamous cell carcinoma of the lung (LSCC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Jul 2021; status: recruiting.
02
Drugs
retlirafusp alfafluzoparib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT04937972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937972.